Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.12.2023 | News item

Falsified Ozempic (semaglutide) and Saxenda (liraglutide)

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The UK Medicines and Healthcare products regulatory Agency (MHRA) is advising that potentially harmful falsified Ozempic (semaglutide) and Saxenda (liraglutide) products have been found in the UK. Healthcare professionals should be vigilant for symptoms linked to hypoglycaemia in patients who may have obtained falsified Ozempic or Saxenda products containing insulin. They should remind patients using Ozempic or Saxenda to always obtain prescription medicines from a registered pharmacy and not to use products they suspect are falsified as this may lead to serious adverse events. Ozempic and Saxenda from legitimate supply chains are unaffected, said the MHRA. …
Metadaten
Titel
Falsified Ozempic (semaglutide) and Saxenda (liraglutide)
Publikationsdatum
01.12.2023
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51307-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Adenosine

Case report

Antineoplastics

Case report

Romiplostim